Combination Liposomal Irinotecan and Pembrolizumab For Triple-Negative Breast Cancer (TNBC) With Brain Metastases (BM)

NCT05255666 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped No drug

Conditions

Triple Negative Breast Cancer
Brain Metastases

Interventions

DRUG: Pembrolizumab
DRUG: Liposomal Irinotecan

Sponsor

Washington University School of Medicine

Collaborators

[object Object]
[object Object]